US EditionEncaleret developer aims for clinical trial in chronic...
Summary by Hypoparathyroidism News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Encaleret developer aims for clinical trial in chronic...
Treatment with the investigational therapy encaleret normalized calcium levels for most people with chronic hypoparathyroidism in a small proof-of-principle study. That’s according to data announced by Bridgebio Pharma, which is developing encaleret with its affiliate Calcilytix Therapeutics. The company said it hopes to launch a clinical trial that could serve as a basis for encaleret’s approval for chronic hypoparathyroidism in 2026. Hypoparat…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
